167 related articles for article (PubMed ID: 29784846)
21. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
22. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.
Benjamin JM; Moore BR; Salman S; Page-Sharp M; Tawat S; Yadi G; Lorry L; Siba PM; Batty KT; Robinson LJ; Mueller I; Davis TM
Antimicrob Agents Chemother; 2015 Jul; 59(7):4260-71. PubMed ID: 25963981
[TBL] [Abstract][Full Text] [Related]
24. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
[TBL] [Abstract][Full Text] [Related]
25. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.
Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Wiesner L; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
J Antimicrob Chemother; 2022 May; 77(6):1733-1737. PubMed ID: 35288747
[TBL] [Abstract][Full Text] [Related]
26. Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.
Moore BR; Benjamin JM; Salman S; Griffin S; Ginny E; Page-Sharp M; Robinson LJ; Siba P; Batty KT; Mueller I; Davis TM
Antimicrob Agents Chemother; 2014 Oct; 58(10):5784-94. PubMed ID: 25049242
[TBL] [Abstract][Full Text] [Related]
27. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
[TBL] [Abstract][Full Text] [Related]
28. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
[TBL] [Abstract][Full Text] [Related]
29. Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine.
Ippolito MM; Jacobson JM; Lederman MM; Winterberg M; Tarning J; Shapiro TA; Flexner C
Clin Infect Dis; 2018 Oct; 67(10):1617-1620. PubMed ID: 29771277
[TBL] [Abstract][Full Text] [Related]
30. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
[TBL] [Abstract][Full Text] [Related]
31. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
32. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
[TBL] [Abstract][Full Text] [Related]
33. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.
Adjei A; Narh-Bana S; Amu A; Kukula V; Nagai RA; Owusu-Agyei S; Oduro A; Macete E; Abdulla S; Halidou T; Sie A; Osei I; Sevene E; Asante KP; Mulokozi A; Compaore G; Valea I; Adjuik M; Baiden R; Ogutu B; Binka F; Gyapong M
Malar J; 2016 Jan; 15():43. PubMed ID: 26818128
[TBL] [Abstract][Full Text] [Related]
34. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
35. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
[TBL] [Abstract][Full Text] [Related]
36. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
[TBL] [Abstract][Full Text] [Related]
37. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.
Olafuyi O; Coleman M; Badhan RKS
Biopharm Drug Dispos; 2017 Nov; 38(8):464-478. PubMed ID: 28710808
[TBL] [Abstract][Full Text] [Related]
38. Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women.
Hughes E; Wallender E; Kajubi R; Jagannathan P; Ochieng T; Kakuru A; Kamya MR; Clark TD; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Clin Infect Dis; 2022 Aug; 75(3):406-415. PubMed ID: 34864925
[TBL] [Abstract][Full Text] [Related]
39. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Green JA; Mohamed K; Goyal N; Bouhired S; Hussaini A; Jones SW; Koh GC; Kostov I; Taylor M; Wolstenholm A; Duparc S
Antimicrob Agents Chemother; 2016 Dec; 60(12):7321-7332. PubMed ID: 27697758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
